For the 598 ( 91 % ) patients with BRAF ( V600E ) disease , median overall survival in the vemurafenib group was 133 months ( 95 % CI 119-149 ) compared with 100 months ( 80-140 ) in the dacarbazine group ( HR 075 [ 95 % CI 060-093 ] ; p = 00085 ) ; median progression-free survival was 69 months ( 95 % CI 62-70 ) and 16 months ( 16-21 ) , respectively ( HR 039 [ 95 % CI 033-047 ] ; p < 00001 ) .